May 02, 2022 / 07:00PM GMT
James Tran - Bloom Burton & Co. - Analyst
Our next session -- our next presentation is by Medicenna Therapeutics. And joining us, we have Fahar Merchant, the President and CEO. We will have five minutes for questions at the end. Fahar, go ahead.
Fahar Merchant - Medicenna Therapeutics Corp. - President & CEO
Okay. All right. Thank you all. Thank you for joining the session. I'd like to thank Bloom Burton for inviting us to present today.
So as introduced, I'm Fahar Merchant, President and CEO of Medicenna. And just to let you know that I will be making forward-looking statements. I encourage you to look at our regulatory filings regarding risks and uncertainties and so on.
So Medicenna is a company that's developing a novel set of therapeutic agents, focused very much in the oncology space, with our focus really in the cytokine or interleukin space, specifically.
And when I talk about cytokines or interleukins, what I refer to is three very specific interleukins namely IL-2, IL-4, and IL-13. And each of these interleukins are
Medicenna Therapeutics Corp at Bloom Burton & Co. Healthcare Investor Conference Transcript
Feb 14, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers